Li Wenfang, Dong Huimin, Huang Yan, Chen Tingjin, Kong Xiangzhan, Sun Hengchang, Yu Xinbing, Xu Jin
Department of Parasitology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.
Key Laboratory for Tropical Disease Control, Sun Yat-sen University, Ministry of Education, Guangzhou, Guangdong, China.
PLoS Negl Trop Dis. 2016 Jun 27;10(6):e0004806. doi: 10.1371/journal.pntd.0004806. eCollection 2016 Jun.
Clonorchis sinensis (C. sinensis) is considered to be an important parasitic zoonosis because it infects approximately 35 million people, while approximately 15 million were distributed in China. Hepatitis B virus (HBV) infection is a major public health issue. Two types of pathogens have the potential to cause human liver disease and eventually hepatocellular carcinoma. Concurrent infection with HBV and C. sinensis is often observed in some areas where C. sinensis is endemic. However, whether C. sinensis could impact HBV infection or vice versa remains unknown.
Co-infection with C. sinensis and HBV develops predominantly in males. Co-infected C. sinensis and HBV patients presented weaker liver function and higher HBV DNA titers. Combination treatment with antiviral and anti-C. sinensis drugs in co-infected patients could contribute to a reduction in viral load and help with liver function recovery. Excretory-secretory products (ESPs) may, in some ways, increase HBV viral replication in vitro. A mixture of ESP and HBV positive sera could induce peripheral blood mononuclear cells (PBMCs) to produce higher level of Th2 cytokines including IL-4, IL-6 and IL-10 compared to HBV alone, it seems that due to presence of ESP, the cytokine production shift towards Th2. C. sinensis/HBV co-infected patients showed higher serum IL-6 and IL-10 levels and lower serum IFN-γ levels.
CONCLUSIONS/SIGNIFICANCE: Patients with concomitant C. sinensis and HBV infection presented weaker liver function and higher HBV DNA copies. In co-infected patients, the efficacy of anti-viral treatment was better in patients who were prescribed with entecavir and praziquantel than entecavir alone. One possible reason for the weaker response to antiviral therapies in co-infected patients was the shift in cytokine production from Th1 to Th2 that may inhibit viral clearance. C. sinensis/HBV co-infection could exacerbate the imbalance of Th1/Th2 cytokine.
华支睾吸虫(C. sinensis)被认为是一种重要的寄生虫人畜共患病,因为它感染了约3500万人,其中约1500万人分布在中国。乙型肝炎病毒(HBV)感染是一个主要的公共卫生问题。这两种病原体都有可能导致人类肝脏疾病并最终引发肝细胞癌。在华支睾吸虫流行的一些地区,经常观察到HBV与华支睾吸虫的合并感染。然而,华支睾吸虫是否会影响HBV感染,反之亦然,仍然未知。
华支睾吸虫与HBV的合并感染主要发生在男性中。华支睾吸虫与HBV合并感染的患者肝功能较弱,HBV DNA滴度较高。在合并感染的患者中,抗病毒药物与抗华支睾吸虫药物联合治疗有助于降低病毒载量并促进肝功能恢复。排泄分泌产物(ESPs)在某些方面可能会增加体外HBV病毒复制。与单独的HBV相比,ESPs和HBV阳性血清的混合物可诱导外周血单个核细胞(PBMCs)产生更高水平的Th2细胞因子,包括IL-4、IL-6和IL-10,似乎由于ESPs的存在,细胞因子产生向Th2偏移。华支睾吸虫/HBV合并感染的患者血清IL-6和IL-10水平较高,血清IFN-γ水平较低。
结论/意义:华支睾吸虫与HBV合并感染的患者肝功能较弱,HBV DNA拷贝数较高。在合并感染的患者中,接受恩替卡韦和吡喹酮治疗的患者抗病毒治疗效果优于单独使用恩替卡韦的患者。合并感染患者对抗病毒治疗反应较弱的一个可能原因是细胞因子产生从Th1向Th2的转变,这可能会抑制病毒清除。华支睾吸虫/HBV合并感染可能会加剧Th1/Th2细胞因子的失衡。